Mid Ohio Oncology/Hematology, Inc., dba The Mark H. Zangmeister Center

Columbus, Ohio 43219

0 studies enrolling now · 8 studies all time

What they study most

Advanced Breast Cancer, Breast Neoplasms, Chemotherapy-induced Nausea and Vomiting, Chronic Idiopathic Thrombocytopenic Purpura, Fallopian Tube Cancer, Graft Vs Host Disease, Idiopathic Thrombocytopenic Purpura, Leukemia, B-cell, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Metastatic Breast Cancer

Studies at this site

• Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. — Running, not enrolling
• Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) — Stopped early
• Connect® Myeloid Disease Registry — Stopped early
• Palbociclib in Real World Practice — Completed
• A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer — Completed
• Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003 — Completed
• Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) — Completed
• Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer — Stopped early